Production (Stage)
Opus Genetics, Inc.
IRD
$1.04
$0.044.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -28.19% | -42.30% | -85.35% | -63.67% | -54.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -28.19% | -42.30% | -85.35% | -63.67% | -54.30% |
| Cost of Revenue | 75.22% | 49.78% | 41.53% | 12.15% | 14.63% |
| Gross Profit | -1,144.42% | -2,156.48% | -139.63% | -108.10% | -93.90% |
| SG&A Expenses | 39.08% | 52.43% | 32.04% | 28.55% | 83.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.34% | 52.19% | 34.56% | 16.25% | 35.46% |
| Operating Income | -198.97% | -222.58% | -201.37% | -183.07% | -165.26% |
| Income Before Tax | -419.27% | -476.82% | -193.52% | -174.28% | -159.39% |
| Income Tax Expenses | -- | -- | -100.61% | -96.19% | -96.19% |
| Earnings from Continuing Operations | -418.72% | -476.13% | -194.58% | -175.60% | -160.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -418.72% | -476.13% | -194.58% | -175.60% | -160.46% |
| EBIT | -198.97% | -222.58% | -201.37% | -183.07% | -165.26% |
| EBITDA | -198.98% | -222.70% | -201.33% | -183.01% | -165.21% |
| EPS Basic | -317.85% | -340.15% | -178.92% | -160.17% | -154.00% |
| Normalized Basic EPS | -124.33% | -141.61% | -177.79% | -158.76% | -152.67% |
| EPS Diluted | -310.27% | -331.92% | -182.45% | -164.60% | -158.16% |
| Normalized Diluted EPS | -119.16% | -135.88% | -181.44% | -163.54% | -157.17% |
| Average Basic Shares Outstanding | 29.25% | 23.76% | 18.22% | 13.92% | 10.00% |
| Average Diluted Shares Outstanding | 27.88% | 22.40% | 15.97% | 14.15% | 10.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |